First-Line Treatment Options for Metastatic Pancreatic Adenocarcinoma

Opinion
Video

Panelists discuss how the current first-line treatment landscape for metastatic pancreatic adenocarcinoma includes NCCN-recommended regimens like FOLFIRINOX, gemcitabine plus nab-paclitaxel, and newest addition NALIRIFOX, with treatment selection guided by toxicity profiles, patient-specific factors, and the importance of germline testing.

Video content above is prompted by the following:

In this Cancer Network Frontline Forum program, Sreenivasa Chandana, MD, PhD and Darshil Shah, MD, MPH discuss navigating first-line therapy options for metastatic pancreatic adenocarcinoma. Dr. Chandana, a gastrointestinal (GI) medical oncologist from the Cancer and Hematology Centers in Grand Rapids, Michigan, specializes in pancreatic cancer research and drug development. Dr. Shah is a GI medical oncologist and director of the gastrointestinal oncology division at Ironwood Cancer and Research Centers in Phoenix, Arizona.

The program serves as an extension of a previous meeting in which expert faculty discussed key clinical data updates for frontline therapy in metastatic pancreatic adenocarcinoma. The 2 physicians plan to review the latest data and share insights on applying this information to clinical practice. They begin by discussing the current treatment landscape for first-line metastatic pancreatic adenocarcinoma therapy.

Dr. Shah explains that the first-line treatment landscape includes multiple NCCN-recommended regimens for patients with ECOG performance status of 0 or 1, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, and the newest addition, NALIRIFOX (based on the NAPOLI-3 study). While each regimen demonstrates efficacy, toxicity profiles and patient-specific factors guide treatment selection. Dr Shah also emphasizes the importance of germline testing, as approximately 10% of pancreatic ductal adenocarcinomas are driven by germline mutations that benefit from platinum-based regimens.

Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
Related Content